Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
docetaxel + pemetrexed
- Development stage
- Phase 2
- Lead developer
- Sanofi
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Docetaxel + pemetrexed is an investigational combination chemotherapy regimen consisting of two small molecule antineoplastic agents, docetaxel (a taxane) and pemetrexed (an antifolate). Both drugs disrupt cell division but through different mechanisms. Docetaxel stabilizes microtubules, inhibiting their depolymerization and thereby blocking mitosis. Pemetrexed inhibits several folate-dependent enzymes involved in the synthesis of thymidine and purine nucleotides, leading to inhibition of DNA and RNA synthesis. This combination has been studied primarily as a second-line treatment for advanced non-small cell lung cancer (NSCLC), with the aim of improving efficacy over monotherapy regimens. However, clinical trials have shown that while both agents are effective as single agents in NSCLC, their combination did not demonstrate additional benefit due to increased toxicity[1][3][2]. The regimen remains investigational without regulatory approval for this specific doublet.
- Brand names
- Alimta + Taxotere
- Other names
- docetaxel and pemetrexeddocetaxel plus pemetrexed
02
Targets
DHFR (Dihydrofolate reductase)GART (GAR transformylase)TS (Thymidylate synthase)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on docetaxel + pemetrexed.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on docetaxel + pemetrexed.